Humanity’s urgent need for a vaccine, or set of vaccines, for SARS-CoV-2 needs no elaboration. Quite simply, this is one of the more pressing scientific/humanitarian needs of the century.
With the Harvard School of Medicine and the Government of India, we are close to launching multiple phase 3 COVID-19 vaccine trials. Through this venture, OpenVax, we seek to fight COVID-19 and future pandemics rapidly and equitably by repurposing existing widely-available off-patent low-cost vaccines with strong safety records.
With the European Vaccine Initiative (EVI), we are working to develop a computational platform to develop a COVID-19 vaccine.
Learn more about our ventures and take part in the fight.
With the Harvard School of Medicine and the Government of India, we are close to launching multiple phase 3 COVID-19 vaccine trials. Through this venture, OpenVax, we seek to fight COVID-19 and future pandemics rapidly and equitably by repurposing existing widely-available off-patent low-cost vaccines with strong safety records.
With the European Vaccine Initiative (EVI), we are working to develop a computational platform to develop a COVID-19 vaccine.
Learn more about our ventures and take part in the fight.
